β
Outcome MeasurePTSD

PCL-5

PTSD Checklist for DSM-5

4 Papers in Blossom

Clinical Thresholds

080
Below threshold
Score 0–30
Probable PTSD
Score 31–80

Outcome Data Across Studies

Reported results for PCL-5 across 3 studies with quantitative data.

Outcome data across 12 study arm–timepoint observations
SD
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic
2024Secondary
Psilocybin(experimental)2815-16.7Δ15.0—
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic
2024Secondary
Niacin (active placebo)(active_comparator)2815-6.7Δ10.7—
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial
2025Secondary
Psilocybin 25 mg(experimental)0————
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial
2025Secondary
Psilocybin 1 mg (control)(inactive)0————
Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)
2026Secondary
TMS-OK(experimental)025———
Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)
2026Secondary
TMS-OK(experimental)4219———
Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)
2026Secondary
TMS-OK(experimental)4924———
Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)
2026Secondary
TMS-OK(experimental)7023———
Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)
2026Secondary
TMS-sham + OK(active_comparator)025———
Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)
2026Secondary
TMS-sham + OK(active_comparator)4219———

Papers Using PCL-5

Open Accessindividual

Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)

This open-label trial (n=25) found that six weeks of low-dose oral ketamine treatment for PTSD was associated with small but significant decreases in both BDNF and VEGF-A blood biomarkers, which were positively correlated with each other, suggesting these two proteins may interact as part of the biological mechanism behind ketamine's effects on PTSD symptoms.

Published
Journal
Psychopharmacology
Authors
Quigley, B. L., Orr, E., Kafka, S., Hajishafiee, M., Bouças, A. P., Wellington, N., Dutton, M., Jones, M., Randall, F., Lagopoulos, J., Can, A. T., Hermens, D. F.
Paywallindividual

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

In this double‑blind, randomised pilot trial of recently detoxified patients with severe alcohol use disorder and comorbid depression, two 25 mg psilocybin‑assisted psychotherapy sessions (versus 1 mg control) were feasible, acceptable and safe. At 12 weeks the 25 mg group showed higher abstinence (55% vs 11%) and significant reductions in percent drinking days and craving frequency, although blinding was imperfect and the study was small and preliminary.

Published
Journal
Addiction
Authors
Luquiens, A., Belahda, D., Graux, C., Igounenc, N., Serrand, C., Rochefort, P., Mura, T., Sergent, F.
Open Accessindividual

Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic

In a double‑blind randomised clinical trial of 30 US frontline clinicians with pandemic‑related depression, a single 25 mg psilocybin session (with preparatory and integration visits) produced a significantly greater reduction in clinician‑rated depressive symptoms at 28 days than 100 mg niacin (mean MADRS change −21.33 vs −9.33; mean difference −12.00, 95% CI −17.67 to −6.33; P < .001). Improvements in burnout and PTSD symptoms were numerically larger with psilocybin but did not reach statistical significance.

Published
Journal
JAMA Network Open
Authors
Back, A., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., Gooley, T. A.
Open Accessindividual

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial

This Phase II clinical trial (n=26) finds that MDMA-assisted psychotherapy (75-125 mg) led to significant and sustained decreases in PTSD (CAPS-IV) scores as compared to an active placebo (30 mg). At the 12-month follow-up, the average CAPS-IV score had dropped from 87 to 39 (67% no longer qualified for PTSD diagnosis).

Published
Journal
Lancet Psychiatry
Authors
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A., Jerome, L., Wagner, M. T., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R.

Quick Facts

Full Name
PTSD Checklist for DSM-5
Domain
PTSD
Papers Indexed
4
Score Range
0–80
Interpretation
Lower = better
All Measures